肝癌缺失-1基因表达与结肠癌分期相关性研究  

The correlation between expression of DLC-1 and colon cancer staging

作　　者：王建纲[1] 邵泉[1] 王英斌[1] 万远廉[2] 

机构地区：[1] 山西医科大学附属太钢总医院普外科,太原030003 [2] 北京大学附属第一医院普外科

出　　处：《肿瘤研究与临床》2014年第4期246-249,共4页Cancer Research and Clinic

摘　　要：目的 探讨肝癌缺失-1（DLC-1）基因mRNA表达与结肠癌分期及淋巴结转移的相关性.方法 收集2009年9月至2011年9月手术切除结肠癌标本共60例,以外伤、结肠憩室、结肠炎手术治疗留取的正常组织10例为对照.采用反转录PCR定量检测结肠癌组织、癌旁组织、正常组织DLC-1基因mRNA的表达.依据TNM分期进行分期,采用直线相关分析DLC-1基因表达与结肠癌分期及淋巴结转移的相关性.结果 结肠癌组织DLC-1基因mRNA的表达水平（0.085±0.004）明显低于癌旁组织（0.562±0.063）,癌旁组织低于正常组织（1.000±0.003）.DLC-1基因mRNA表达水平与结肠癌分期呈负相关（r=0.51,P＜ 0.01）,DLC-1基因mRNA表达水平与淋巴结转移呈负相关（r=0.46,P＜ 0.05）.结论 DLC-1基因mRNA表达与病理学分期、淋巴结转移率呈负相关,DLC-1基因在结肠癌发生、发展中扮演重要角色,可能是研究结肠癌新的突破口.Objective To investigate the relationship between the expression level of deleted in liver cancer-1 （DLC-1） gene and colon cancer staging or lymph nodes metastatic ratio.Methods Total 60 resection specimens were collected from colon cancer patients between September 2009 and September 2011,and 10 resection specimens from patients with trauma,colonic diverticulitis and colitis were used as the control.The DLC-1 mRNA level was measured with real time quantitative RT-PCR in colon cancer patients and the control group.TNM system was used for colon cancer staging.The linear correlation analysis was performed to determine the relationship between DLC-1 expression level and colon cancer staging or lymph nodes metastatic ratio.Results The mRNA level of DLC-1 was significantly reduced in colon cancer tissues in comparison to that in adjacent normal tissues,while adjacent tissues showed significantly lower DLC-1 level than normal clone tissues.The expression of DLC-1 was negatively correlated with both colon cancer stage and the lymph nodes metastatic ratio （r =0.46,P 〈 0.05）.Conclusions DLC-1 expression was negatively correlated with pathological stage and lymph node metastasis ratio,indicating a critical role of DLC-1 gene in colon cancer genesis,which provide a possible new direction for colon cancer research.

关 键 词：基因 肝癌缺失-1 结肠肿瘤 肿瘤分期 淋巴转移 

分 类 号：R735.35[医药卫生—肿瘤]